Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic, Inc. - Common Stock (NQ:IMUX)

0.9287 -0.0507 (-5.18%)
Streaming Delayed Price Updated: 10:55 AM EDT, Aug 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Immunic, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Immunic (IMUX) Q2 Loss Widens 25%
Via The Motley Fool
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Via Stocktwits
Immunic to Participate in Scientific and Industry Conferences in May
Via Stocktwits
Topics Economy
Immunic, Inc. Announces Proposed Public Offering
Via Stocktwits
Topics Regulatory Compliance
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
Via Stocktwits
Immunic to Participate in Investor, Scientific and Industry Conferences in June
Via Stocktwits
Topics Intellectual Property
IMUX Stock Earnings: Immunic Misses EPS for Q1 2024
IMUX stock results show that Immunic missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Immunic's Earnings Outlook
 
Via Benzinga
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
Via Stocktwits
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Via Stocktwits
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Via Stocktwits
Let's take a look at the stocks that are in motion in today's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Wednesday's session: top gainers and losers
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Wednesday's session: gap up and gap down stocks
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
These stocks that are showing activity before the opening bell on Wednesday.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Immunic Stock Draws Investor Attention On $5.1M Registered Direct Offering: Retail’s On Wait-And-Watch Mode
Immunic intends to use the net proceeds from the proposed offering to fund its clinical trials and operations and for other general corporate purposes. 
Via Stocktwits
Topics Intellectual Property Lawsuit
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying
While speculative ideas are treacherous, you can possibly reduce your blood pressure with these penny stocks with insider buying. 
Via InvestorPlace
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day 
Via News Direct
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Immunic chief medical officer discusses promising treatments to mark World IBD Day 
Via News Direct
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day 
Via News Direct
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones 
Via News Direct
Topics Intellectual Property
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal 
Via News Direct
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
--News Direct-- 
Via News Direct
Immunic And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
What's Going On With Immunic Stock?
Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.